180 related articles for article (PubMed ID: 36399467)
21. Tumor-derived exosomes encapsulating miR-34a promote apoptosis and inhibit migration and tumor progression of colorectal cancer cells under in vitro condition.
Hosseini M; Baghaei K; Amani D; Ebtekar M
Daru; 2021 Dec; 29(2):267-278. PubMed ID: 34405380
[TBL] [Abstract][Full Text] [Related]
22. CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.
Zhang N; Fan J; Deng Z
Anticancer Drugs; 2022 Jun; 33(5):437-447. PubMed ID: 35324518
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding RNA SNHG16 contributes to the development of bladder cancer via regulating miR-98/STAT3/Wnt/β-catenin pathway axis.
Feng F; Chen A; Huang J; Xia Q; Chen Y; Jin X
J Cell Biochem; 2018 Nov; 119(11):9408-9418. PubMed ID: 30132983
[TBL] [Abstract][Full Text] [Related]
24. CircRNA VIM silence synergizes with sevoflurane to inhibit immune escape and multiple oncogenic activities of esophageal cancer by simultaneously regulating miR-124/PD-L1 axis.
Gao C; Xu YJ; Qi L; Bao YF; Zhang L; Zheng L
Cell Biol Toxicol; 2022 Oct; 38(5):825-845. PubMed ID: 34018092
[TBL] [Abstract][Full Text] [Related]
25. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.
Zhang H; Zhu C; He Z; Chen S; Li L; Sun C
J Exp Clin Cancer Res; 2020 Sep; 39(1):179. PubMed ID: 32891166
[TBL] [Abstract][Full Text] [Related]
26. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
[TBL] [Abstract][Full Text] [Related]
27. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
Wei S; Wang K; Huang X; Zhao Z; Zhao Z
Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
[TBL] [Abstract][Full Text] [Related]
29. YY1-induced long non-coding RNA PSMA3 antisense RNA 1 functions as a competing endogenous RNA for microRNA 214-5p to expedite the viability and restrict the apoptosis of bladder cancer cells via regulating programmed cell death-ligand 1.
Zhang M; Xu Y; Yin S; Qiu F
Bioengineered; 2021 Dec; 12(2):9150-9161. PubMed ID: 34720049
[TBL] [Abstract][Full Text] [Related]
30. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
31. Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs/G3BP1/PD-L1 axis.
Li C; Pan B; Wang X; Liu X; Qin J; Gao T; Sun H; Pan Y; Wang S
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1965-1982. PubMed ID: 35357586
[TBL] [Abstract][Full Text] [Related]
32. LncRNA FOXD3-AS1 promotes proliferation, invasion and migration of cutaneous malignant melanoma via regulating miR-325/MAP3K2.
Chen X; Gao J; Yu Y; Zhao Z; Pan Y
Biomed Pharmacother; 2019 Dec; 120():109438. PubMed ID: 31541886
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z
Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874
[TBL] [Abstract][Full Text] [Related]
34. LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer.
Zhang W; Xin J; Lai J; Zhang W
Immunobiology; 2022 Jan; 227(1):152163. PubMed ID: 34896914
[TBL] [Abstract][Full Text] [Related]
35. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.
Li Y; Zhou T; Cheng X; Li D; Zhao M; Zheng WV
Bioengineered; 2022 Mar; 13(3):4730-4743. PubMed ID: 35184646
[TBL] [Abstract][Full Text] [Related]
36. Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.
Chen Y; Li F; Li D; Liu W; Zhang L
Clin Immunol; 2021 Jun; 227():108728. PubMed ID: 33878452
[TBL] [Abstract][Full Text] [Related]
37. LncRNA NEAT1 knockdown attenuates autophagy to elevate 5-FU sensitivity in colorectal cancer via targeting miR-34a.
Liu F; Ai FY; Zhang DC; Tian L; Yang ZY; Liu SJ
Cancer Med; 2020 Feb; 9(3):1079-1091. PubMed ID: 31802650
[TBL] [Abstract][Full Text] [Related]
38. LncRNA ANRIL promotes cell proliferation, migration and invasion during acute myeloid leukemia pathogenesis via negatively regulating miR-34a.
Wang CH; Li QY; Nie L; Ma J; Yao CJ; Chen FP
Int J Biochem Cell Biol; 2020 Feb; 119():105666. PubMed ID: 31830533
[TBL] [Abstract][Full Text] [Related]
39. HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis.
Zeng C; Ye S; Chen Y; Zhang Q; Luo Y; Gai L; Luo B
J Immunol Res; 2021; 2021():9289719. PubMed ID: 34988230
[TBL] [Abstract][Full Text] [Related]
40. lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway.
Li Y; Li C; Li D; Yang L; Jin J; Zhang B
Onco Targets Ther; 2019; 12():2649-2660. PubMed ID: 31040703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
